Key clinical point: For patients with high-risk stage II colorectal cancer, 3 months of adjuvant therapy with capecitabine plus oxaliplatin (CAPOX) may be as effective as a 6-month regimen, but with fewer adverse events.
Major finding: Five-year relapse-free survival rates were similar in patients who received 3 months of CAPOX and those who received 6 months of CAPOX, with a 0.76% difference favoring the 6-month arm.
Study details: TOSCA was a phase 3 noninferiority trial of 1,254 patients with high-risk stage II resected colorectal cancer.
Disclosures: The study was funded by the Italian Group for the Study of Digestive Tract Cancers (GISCAD) Foundation and Agenzia Italiana del Farmaco. The investigators disclosed relationships with Servier, Merck, Bristol-Myers Squibb, and other companies.
Petrelli F et al. JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.6486.